Interpace Diagnostics Group (IDXG)
OTHER OTC:IDXG
Want to see IDXG full AI Analyst Report?
IDXG Stock Chart & Stats
$0.94
$0.00(0.00%)
At close: 4:00 PM EST
$0.94
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.64 - $2.40
Previous CloseN/A
Volume34.00
Average Volume (3M)11.58K
Market Cap
$55.40M
Enterprise Value$7.53M
Total Cash (Recent Filing)$2.50M
Total Debt (Recent Filing)$1.18M
Price to Earnings (P/E)<0.1
Beta1.40
Next Earnings
May 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)5.57
Shares Outstanding27,700,905
10 Day Avg. Volume15,402
30 Day Avg. Volume11,583
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.24
Price to Sales (P/S)0.14
P/FCF Ratio0.99
Enterprise Value/Market Cap0.14
Enterprise Value/Revenue0.19
Enterprise Value/Gross Profit0.31
Enterprise Value/Ebitda1.58
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Reduced Leverage / Positive EquityThe company’s shift to very low debt and a return to positive equity in 2025 materially improves financial flexibility. This durable balance-sheet repair lowers insolvency risk, supports investment or M&A optionality, and enhances ability to execute multi‑quarter strategic plans without heavy external financing.
Consistent Recent Cash GenerationPositive operating and free cash flow across three consecutive years, with FCF up strongly in 2025, signals sustainable internal funding for operations and reinvestment. Reliable cash conversion reduces dependence on external capital and supports durable margin maintenance and strategic initiatives over the next several quarters.
Strategic Pivot, Guidance, And Capital SimplificationManagement’s pivot to focused thyroid testing with explicit 2026 revenue guidance and a simplified all-common equity structure are structural moves that can sharpen strategy and investor clarity. Coupled with a clean balance sheet and Nasdaq uplisting intent, this enhances long-term access to capital and corporate governance profiles.
Bears Say
Uneven Revenue MomentumIntermittent revenue declines undermine predictability of top-line growth and constrain the durability of profit gains. Persistent volatility in sales complicates capacity planning, R&D prioritization, and margin leverage, raising execution risk for multi-quarter targets and any reliance on sustained organic expansion.
Earnings Quality ConcernsA materially higher reported net margin versus operating/EBITDA margins signals potential one-time gains or non-operating items inflating headline profitability. This raises risk that reported earnings won’t persist, complicating forecasting and reducing confidence that margins reflect recurring operating performance over the next several quarters.
Historical Financial InstabilityAlthough recent balance-sheet metrics improved, a prior multi-year history of negative equity and volatile returns indicates execution and capital-structure fragility. That track record increases the probability that setbacks or cyclical pressures could reintroduce balance-sheet stress, limiting long-term reliability of recent gains.
Interpace Diagnostics Group News
IDXG FAQ
What was Interpace Diagnostics Group’s price range in the past 12 months?
Interpace Diagnostics Group lowest stock price was $0.64 and its highest was $2.40 in the past 12 months.
What is Interpace Diagnostics Group’s market cap?
Interpace Diagnostics Group’s market cap is $55.40M.
When is Interpace Diagnostics Group’s upcoming earnings report date?
Interpace Diagnostics Group’s upcoming earnings report date is May 07, 2026 which is in 2 days.
How were Interpace Diagnostics Group’s earnings last quarter?
Interpace Diagnostics Group released its earnings results on Mar 30, 2026. The company reported $0.818 earnings per share for the quarter, beating the consensus estimate of N/A by $0.818.
Is Interpace Diagnostics Group overvalued?
According to Wall Street analysts Interpace Diagnostics Group’s price is currently Overvalued.
Does Interpace Diagnostics Group pay dividends?
Interpace Diagnostics Group does not currently pay dividends.
What is Interpace Diagnostics Group’s EPS estimate?
Interpace Diagnostics Group’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Interpace Diagnostics Group have?
Interpace Diagnostics Group has 27,700,905 shares outstanding.
What happened to Interpace Diagnostics Group’s price movement after its last earnings report?
Interpace Diagnostics Group reported an EPS of $0.818 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 13.855%.
Which hedge fund is a major shareholder of Interpace Diagnostics Group?
Currently, no hedge funds are holding shares in IDXG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Interpace Diagnostics Group
Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; PanDNA, a molecular only version of PancraGEN that provides physicians a snapshot of a limited number of factors; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.
Technical Analysis
―
ENDRA Life Sciences
―
Intelligent Bio Solutions
―
―
bioAffinity Technologies, Inc.
―
Ownership Overview
83.99% Insiders
<0.01% Other Institutional Investors
16.00% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---